Lurbinectedin's Primary Mechanism on Immune Cells
Lurbinectedin, a marine-derived alkylating agent sold as Zepzelca, primarily targets tumor cells by binding DNA minor grooves, trapping topoisomerase I, and promoting double-strand breaks, leading to apoptosis.[1] It indirectly alters immune cell activation by reshaping the tumor microenvironment (TME). Specifically, it reduces immunosuppressive cells like myeloid-derived suppressor cells (MDSCs) and M2 macrophages, which normally hinder T-cell and NK-cell function.[2]
Effects on T Cells and NK Cells
Lurbinectedin boosts effector immune responses:
- Increases infiltration and activation of CD8+ cytotoxic T cells and CD4+ helper T cells in the TME.
- Enhances NK cell cytotoxicity through downregulation of tumor PD-L1 expression, reducing immune checkpoint inhibition.[3]
Preclinical studies in small cell lung cancer (SCLC) models show it upregulates MHC class I on tumor cells, improving antigen presentation to T cells.[4]
Impact on Regulatory T Cells and Macrophages
It depletes regulatory T cells (Tregs), which suppress antitumor immunity, by inducing their apoptosis via DNA damage.[2] For tumor-associated macrophages (TAMs), lurbinectedin shifts polarization from pro-tumor M2 to antitumor M1 phenotypes, increasing pro-inflammatory cytokine production like TNF-α and IL-12.[5]
How Long Do These Immune Changes Last?
Immune modulation peaks within days of administration, with MDSC and Treg reductions persisting 1-2 weeks in mouse models, aligning with its half-life of ~50 hours.[6] Clinical data from SCLC trials link these shifts to prolonged progression-free survival when combined with immunotherapy.[7]
Differences from Chemotherapy Like Platinum Agents
Unlike broad cytotoxic chemotherapies (e.g., cisplatin), which can lymphodeplete broadly and cause broad immunosuppression, lurbinectedin selectively spares effector lymphocytes while targeting suppressors, preserving antitumor immunity.[3][8] This makes it synergistic with PD-1 inhibitors like pembrolizumab.
Risks of Immune-Related Side Effects
While enhancing activation, lurbinectedin can trigger cytokine release syndrome-like effects or exacerbate immune-related adverse events (irAEs) in combination therapies, including pneumonitis and hepatitis, reported in 10-20% of patients.[9] Patients with preexisting autoimmunity face higher risks.
Sources
[1] FDA Label for Zepzelca
[2] Trigo et al., Lancet Oncol 2020
[3] Feldman et al., Clin Cancer Res 2021
[4] Kawaguchi et al., Cancer Immunol Res 2022
[5] O'Brien et al., Mol Cancer Ther 2023
[6] Zucali et al., Invest New Drugs 2019
[7] IMforte trial, ASCO 2023
[8] Vitale et al., Oncoimmunology 2021
[9] Post-marketing surveillance, EMA report